Lupin has introduced Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials in the United States after Lupin’s alliance partner, ForDoz Pharma Corporation, USA (ForDoz), received approval for its ANDA from the United States Food and Drug Administration (USFDA).

Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials is a generic equivalent of Doxil (Liposomal), of Baxter Healthcare Corporation, indicated for the treatment of Ovarian Cancer, Acquired Immune Deficiency Syndrome (AIDS)-related Kaposi’s Sarcoma, and Multiple Myeloma.

Doxorubicin Hydrochloride Liposome Injection (RLD Doxil (Liposomal)) had an estimated annual sale of USD 40.9 million in the US.

Lupin ed is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the US across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health.